U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Dailey JH, Glassman P, McDonagh M, et al. Drug Class Review: Newer Antiplatelet Agents: Final Report Update 1 [Internet]. Portland (OR): Oregon Health & Science University; 2007 Apr.

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Drug Class Review: Newer Antiplatelet Agents

Drug Class Review: Newer Antiplatelet Agents: Final Report Update 1 [Internet].

Show details

Appendix C. Bibliography of Excluded Articles

  1. Erratum: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death , myocardial infarction, and stroke in high risk patients (BMJ (12 January) (71)). BMJ 2002;324(7330):141.
  2. Albers GW, Amarenco P. Combination therapy with clopidogrel and aspirin: can the CURE results be extrapolated to cerebrovascular patients? Stroke 2001;32(12):2948–9.
  3. Albiero R, Hall P, Itoh A, et al. Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy. Circulation 1997;95(5):1145–56.
  4. Algra A, van GJ. Is clopidogrel superior to aspirin in secondary prevention of vascular disease? CCTCM. 2000;1(3 ):143–145.
  5. Angioi M, Danchin N, Alla F, et al. Long - term outcome in patients treated by intracoronary stenting with ticlopidine and aspirin, and deleterious prognostic role of unstable angina pectoris. Am J Cardio. 2000;85(9 ):1065–1070.
  6. Ashby DT, Dangas G, Mehran R, et al. Comparison of one-year outcomes after percutaneous coronary intervention among current smokers , ex-smokers, and nonsmokers. Am J Cardiol 2002;89(2 ):221–224.
  7. Ashby DT, Mehran R, Aymong EA, et al. Comparison of outcomes in men versus women having percutaneous coronary interventions in small coronary arteries. Am J Cardiol 2003;91(8 ):979–981.
  8. Baigent C, Sudlow C, Collins R, et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death , myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329 ):71–86.
  9. Becquemin JP. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine apres Pontage Femoro-Poplite and the Association Universitaire de Recherche en Chirurgie. N Engl J Med 1997;337(24):1726–31.
  10. Bednar MM, Gross CE. Antiplatelet therapy in acute cerebral ischemia. Stroke 1999;30(4):887–93.
  11. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000;342(24):1773–7.
  12. Bennett CL, Davidson CJ, Raisch DW, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 1999;159(21):2524–8.
  13. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 1998;128(7):541–4.
  14. Berger PB, Bell MR, Grill DE, et al. Frequency of adverse clinical events in the 12 months following successful intracoronary stent placement in patients treated with aspirin and ticlopidine (without warfarin). Am J Cardiol 1998;81(6 ):713–718.
  15. Berger PB, Bell MR, Hasdai D, et al. Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. Circulation 1999;99(2 ):248–53.
  16. Berger PB, Bell MR, Rihal CS, et al. Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol 1999;34(7):1891–4.
  17. Berger PB, Mahaffey KW, Meier SJ, et al. Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. Am Heart J 2002;143(5):841–6.
  18. Berger PB, Vladimir D, Penn IM, et al. Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the total occlusion study of Canada (TOSCA). Am Heart J 2001;142(5):776–781.
  19. Berglund U, Lindahl T. Enhanced onset of platelet inhibition with a loading dose of ticlopidine in ASA-treated stable coronary patients. Int J Cardiol 1998;64(2):215–7.
  20. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998;98 (16):1597–603.
  21. Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102(6):624–9.
  22. Bhatt DL, Chew DP, Hirsch AT, et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001;103(3):363–8.
  23. Bhatt DL, Hirsch AT, Ringleb PA, et al. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. Am Heart J 2000;140(1):67–73.
  24. Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90(6):625–8.
  25. Blecic S. Atherothrombotic events often indicate disseminated atherosclerosis: data from CAPRIE. Cerebrovas Dis 1998;8:34.
  26. Boysen G. Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis. J Intern Med 1999;246(3):239–45.
  27. Budaj A, Yusuf S, Mehta SR, et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 2002;106( 13):1622–6.
  28. Cannon CP. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am J Cardiol 2002;90( 7):760–2.
  29. Caro JJ, Migliaccio-Walle K. Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events. Am J Med 1999;107(6):568–72.
  30. Chan AW, Moliterno DJ, Berger PB, et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol 2003;42(7):1188–95.
  31. Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus Aspirin and Esomeprazole to Prevent Recurrent Ulcer Bleeding. N Engl J Med 2005;352(3):238–244.
  32. Cin VG, Temizhan A, Pekdemir H, et al. The effects of ticlopidine in acute myocardial infarction as an adjunctive treatment to aspirin in an intermediate term setting. Turkish Journal of Medical Sciences 2002;32(4):329–334.
  33. Claeys MJ, Van Der Planken MG, Michiels JJ, et al. Comparison of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention. Blood Coagul Fibrinolysis 2002;13(4):283–8.
  34. Coccheri S. Distribution of symptomatic atherothrombosis and influence of atherosclerotic disease burden on risks of secondary ischaemic events: results from CAPRIE. Eur Heart J 1998;19(Suppl):227.
  35. Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 2004;110(16 ):2361–2367.
  36. Collins TC, Souchek J, Beyth RJ. Benefits of antithrombotic therapy after infrainguinal bypass grafting: A meta-analysis. Am J Med 2004;117(2 ):93–99.
  37. Connolly DL, Lip GYH, Chin BSP . ABC of antithrombotic therapy: Antithrombotic strategies in acute coronary syndromes and percutaneous coronary interventions. BMJ 2002;325(7377 ):1404–1407.
  38. Cosmi B, Rubboli A, Castelvetri C, et al. Ticlopidine versus oral anticoagulation for coronary stenting. Cochrane Database Syst Rev 2001;(4):CD002133.
  39. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103(15):1967–71.
  40. De Schryver EL, Algra A, van Gijn J. Cochrane review: dipyridamole for preventing major vascular events in patients with vascular disease. Stroke 2003;34(8):2072–80.
  41. Diener HC. Dipyridamole trials in stroke prevention. Neurology 1998;51(3 Suppl 3):S17–9.
  42. Diener HC, Bogousslavsky J, Brass LM, et al. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. Cerebrovasc Dis 2004;17(2–3):253–61.
  43. Dippel DW. The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial. Thromb Res 1998;92(1 Suppl 1):S13–6.
  44. Dorffler-Melly J, Buller HR, Koopman MM, et al. Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database Syst Rev 2003;(4):CD000536.
  45. Duran E, Canbaz S, Ege T, et al. Aspirin versus clopidogrel for synthetic graft patency after peripheral arterial bypass grafting. Platelets 2001;12(8):503–4.
  46. Easton JD. Benefit of clopidogrel in patients with evidence of cerebrovascular disease. Neurology 1998;50:PO3081.
  47. Edmondson RA , Cohen AT, Das SK, et al. Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet 1994;344(8927):914–8.
  48. Elsner M, Peifer A, Drexler M, et al. Clinical outcome at six months of coronary stenting followed by ticlopidine monotherapy. Am J Cardiol 1998;81(2):147–51.
  49. Englberger L, Faeh B, Berdat PA, et al. Impact of clopidogrel in coronary artery bypass grafting. Eur J Cardiothorac Surg 2004;26(1):96–101.
  50. Fisher LD, Gent M, Buller HR. Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. Am Heart J 2001;141(1):26–32.
  51. Forbes CD. Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study. Thromb Res 1998;92(1 Suppl 1):S1–6.
  52. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1(8649): 1215–20.
  53. Gerschutz GP, Bhatt DL. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable? Am Heart J 2003;145(4):595–601.
  54. Girolami B, Bernardi E, Prins MH, et al. Antiplatelet therapy and other interventions after revascularisation procedures in patients with peripheral arterial disease: a meta-analysis. Eur J Vasc Endovasc Surg 2000; 19(4):370–80.
  55. Hacke W, Hirsch AT, Topol EJ. The benefit of clopidogrel over aspirin is amplified in high-risk subgroups with a prior history of ischaemic events. Eur Heart J 1999;20:abstract supplement.
  56. Hankey G. The risk of vascular ischaemic events in patients with various clinical manifestations of atherothrombosis: data from CAPRIE. Cerebrovas Dis 1998;8:30.
  57. Hankey GJ. Clopidogrel and thrombotic thrombocytopenic purpura. Lancet 2000 ;356(9226):269–70.
  58. Harker LA, Boissel JP, Pilgrim AJ, et al. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf 1999;21(4):325–35.
  59. Helft G, Osende JI, Worthley SG, et al. Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol 2000;20 (10):2316–21.
  60. Hoffmann R, Takimoglu-Boerekci M, Langenberg R, et al. Randomized comparison of direct stenting with predilatation followed by stenting on vessel trauma and restenosis. Am Heart J 2004;147(4).
  61. Hongo RH, Ley J, Dick SE, et al. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002;40(2):231–7.
  62. Ip RJ, Korban E, Tepper D. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin versus after the placement of coronary artery stents. Cardiovasc Rev Rep 2003;24(5):283–284.
  63. Jauhar R, Bergman G, Savino S, et al. Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting. Am J Cardiol 1999;84(6):726–8, A8.
  64. Kamishirado H, Inoue T, Mizoguchi K, et al. Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. Am Heart J 2002;144(2):303–8.
  65. Karabulut H, Toraman F, Evrenkaya S, et al. Clopidogrel does not increase bleeding and allogenic blood transfusion in coronary artery surgery. Eur J Cardiothorac Surg 2004;25(3):419–23.
  66. Kastrati A, Schomig A, Dirschinger J, et al. A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries. Circulation 2000;102(21):2593–8.
  67. Kastrati A, Schuhlen H, Hausleiter J, et al. Restenosis after coronary stent placement and randomization to a 4–week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial. Circulation 1997;96(2):462–7.
  68. Khot UN, Nissen SE. Is CURE a cure for acute coronary syndromes? Statistical versus clinical significance. J Am Coll Cardiol 2002;40(2):218–9.
  69. Leavey SF, Weinberg J. Thrombotic thrombocytopenic purpura associated with ticlopidine therapy. J Am Soc Nephrol 1997;8(4):689–93.
  70. Love BB, Biller J, Gent M. Adverse haematological effects of ticlopidine. Drug Safety 1998;19(2):89–98.
  71. Lowenthal A, Buyse M. Secondary prevention of stroke: does dipyridamole add to aspirin? Acta Neurol Belg 1994;94(1):24–34.
  72. Machraoui A, Germing A, Lindstaedt M, et al. Efficacy and safety of ticlopidine monotherapy versus ticlopidine and aspirin after coronary artery stenting: follow-up results of a randomized study. J Invasive Cardiol 2001;13(6):431–6.
  73. MacWalter RS, Shirley CP. A benefit-risk assessment of agents used in the secondary prevention of stroke. Drug Saf 2002;25(13):943–63.
  74. Maier C, Gleim M, Weiss T, et al. Severe bleeding following lumbar sympathetic blockade in two patients under medication with irreversible platelet aggregation inhibitors. Anesthesiology 2002;97(3):740–3.
  75. Mathew V, Berger PB, Lennon RJ, et al. Comparison of percutaneous interventions for unstable angina pectoris in patients with and without previous coronary artery bypass grafting. Am J Cardiol 2000;86(9):931–937.
  76. Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005;111(17):2233–40
  77. Mehta SR, Yusuf S. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000;21(24):2033–41.
  78. Mishkel GJ, Aguirre FV, Ligon RW, et al. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. J Am Coll Cardiol 1999;34(7):1884–90.
  79. Mitka M. Results of CURE trial for acute coronary syndrome. JAMA 2001;285(14):1828–9.
  80. Mulder BJ, van der Doef RM, van der Wall EE, et al. Effect of various antithrombotic regimens (aspirin, aspirin plus dipyridamole, anticoagulants) on the functional status of patients and grafts one year after coronary artery bypass grafting. Eur Heart J 1994;15(8):1129–34.
  81. Nacul FE, de Moraes E, Penido C, et al. Massive nasal bleeding and hemodynamic instability associated with clopidogrel. Pharm World Sci 2004;26(1):6–7.
  82. Nagaoka N, Matsubara T, Okazaki K, et al. Comparison of ticlopidine and cilostazol for the prevention of restenosis after percutaneous transluminal coronary angioplasty. Jpn Heart J 2001;42(1):43–54.
  83. Nair GV, Davis CJ, McKenzie ME, et al. Aspirin in patients with coronary artery disease: is it simply irresistible? J Thromb Thrombolysis 2001;11(2):117–26.
  84. Pache J, Kastrati A, Mehilli J, et al. Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen. Catheter Cardiovasc Interv 2002;55(4):436–41.
  85. Page Y, Tardy B, Zeni F, et al . Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet 1991;337(8744):774–6.
  86. Park SW, Lee CW, Kim HS, et al . Comparison of cilostazol versus ticlopidine therapy after stent implantation. Am J Cardiol 1999;84(5):511–4.
  87. Pasqualini L , Pirro M, Lombardini R, et al. A human model of platelet-leukocyte adhesive interactions during controlled ischaemia in patients with peripheral vascular disease. J Clin Pathol 2002;55(12):946–50.
  88. Payne DA, Jones CI, Hayes PD, et al. Beneficial effects of clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy. Circulation 2004;109(12):1476–81.
  89. Pekdemir H, Cin VG, Camsari A, et al. A comparison of 1-month and 6-month clopidogrel therapy on clinical and angiographic outcome after stent implantation. Heart Vessels 2003;18(3):123–9.
  90. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108(14):1682–7.
  91. Ringleb PA, Bhatt DL, Hirsch AT, et al. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004 ;35(2):528–32.
  92. Rosendaal FR, Algra A. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1997;150(1):85, 87.
  93. Rothwell PM. Lessons from MATCH for future randomised trials in secondary prevention of stroke. Lancet 2004;364(9431):305–7.
  94. Sabatine, M. S.; Cannon, C. P.; Gibson, C. M.; Lopez-Sendon, J. L.; Montalescot, G.; Theroux, P.; Claeys, M. J.; Cools, F.; Hill, K. A.; Skene, A. M.; McCabe, C. H., and Braunwald, E. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005 Mar 24; 352(12):1179–89.
  95. Saw J, Topol EJ, Steinhubl SR, et al. Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. Am J Cardiol 2004;94(5):623–5.
  96. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334(17):1084–9.
  97. Schuhlen H, Hadamitzky M, Walter H, et al. Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial. Circulation 1997;95(8):2015–21.
  98. Schuhlen H, Kastrati A, Pache J, et al. Sustained benefit over four years from an initial combined antiplatelet regimen after coronary stent placement in the ISAR trial. Intracoronary Stenting and Antithrombotic Regimen. Am J Cardiol 2001;87(4):397–400.
  99. Schulman SP. Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes. JAMA 2004;292(15):1875–82.
  100. Scrutinio D, Cimminiello C, Marubini E, et al. Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. J Am Coll Cardiol 2001;37(5):1259–65.
  101. Shlansky-Goldberg R. Platelet aggregation inhibitors for use in peripheral vascular interventions: what can we learn from the experience in the coronary arteries? J Vasc Interv Radiol 2002;13(3):229–46.
  102. Siegel AM, Sandor P, Kollias SS, et al. Transient ischemic attacks after dipyridamole-aspirin therapy. J Neurol 2000;247(10):807–8.
  103. Sivenius J, Cunha L, Diener HC, et al. Second European Stroke Prevention Study: antiplatelet therapy is effective regardless of age. ESPS2 Working Group. Acta Neurol Scand 1999;99(1):54–60.
  104. Sivenius J, Riekkinen PJ Sr, Laakso M. Antiplatelet treatment in elderly people with transient ischaemic attacks or ischaemic strokes. BMJ 1995;310(6971):25–6.
  105. Steinhubl SR, Ellis SG, Wolski K, et al. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation 2001;103(10):1403–9.
  106. Steinhubl SR, Tan WA, Foody JM, et al. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA 1999;281(9):806–10.
  107. Steinhubl SR, Topol EJ. Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting. J Thromb Thrombolysis 1999;7(3):227–31.
  108. Tanabe Y, Ito E, Nakagawa I, et al. Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine. Int J Cardiol 2001;78(3):285–91.
  109. Tijssen JG. Low-dose and high-dose acetylsalicylic acid, with and without dipyridamole: a review of clinical trial results. Neurology 1998;51(3 Suppl 3):S15–6.
  110. Tsai HM, Rice L, Sarode R, et al. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000;132(10):794–9.
  111. Tsuruta M, Utsunomiya T, Yoshida K, et al. Effect of ticlopidine on exercise-induced platelet aggregation and exercise tolerance time in patients with ischemic heart disease. J Cardiovasc Pharmacol 1999;33(4):659–64.
  112. Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998;98 (20):2126–32.
  113. van der Heijden DJ, Westendorp IC, Riezebos RK, et al. Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation. J Am Coll Cardiol 2004;44(1):20–4.
  114. van der Meer J, Brutel de la Riviere A, van Gilst WH, et al. Effects of low dose aspirin (50 mg/day), low dose aspirin plus dipyridamole, and oral anticoagulant agents after internal mammary artery bypass grafting: patency and clinical outcome at 1 year. CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands. Prevention of Coronary Artery Bypass Graft Occlusion by Aspirin, Dipyridamole and Acenocoumarol/Phenprocoumon Study. J Am Coll Cardiol 1994;24(5):1181–8.
  115. Wienbergen H, Gitt AK, Schiele R, et al. Different treatments and outcomes of consecutive patients with non-ST-elevation myocardial infarction depending on initial electrocardiographic changes (results of the Acute Coronary Syndromes. Am J Cardiol 2004;93( 12):1543–6.
  116. Wong NN. Aggrenox: an aspirin and extended-release dipyridamole combination. Heart Dis 2001;3(5):340–6.
  117. Yip HK, Chang HW, Wu CJ, et al. A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction. Jpn Heart J 2000;41 (6):697–711.
  118. Yoon Y, Shim WH, Lee DH, et al. Usefulness of cilostazol versus ticlopidine in coronary artery stenting. Am J Cardiol 1999;84(12):1375–80.
  119. Yusuf S, Mehta SR, Zhao F, et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003;107(7):966–72.
  120. Zachry WM, Wilson JP, Lawson KA, et al. Procedure costs and outcomes associated with pharmacologic management of peripheral arterial disease in the Department of Defense. Clin Ther 1999;21(8):1358–69.
  121. Zakarija A, Bandarenko N, Pandey DK, et al. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke 2004;35(2):533–7.

Update (July 2006)

  1. Summaries for patients. Is it cost-effective to treat high-risk cardiac patients with clopidogrel plus aspirin as opposed to aspirin alone? Ann Intern Med. 2005 Feb 15; 142(4):I53.
  2. Who needs Plavix? This super aspirin is meant mainly for people at high risk of having a heart attack or stroke. Harv Heart Lett. 2005 Mar; 15(7):6–7.
  3. Abramson, B. L.; Huckell, V.; Anand, S.; Forbes, T.; Gupta, A.; Harris, K.; Junaid, A.; Lindsay, T.; McAlister, F.; Roussin, A.; Saw, J.; Teo, K. K.; Turpie, A. G., and Verma, S. Canadian Cardiovascular Society Consensus Conference: peripheral arterial disease - executive summary. Can J Cardiol. 2005 Oct; 21(12):997–1006.
  4. Adelola, O. A.; Ullah, I., and Fenton, J. E. Clopidogrel induced oral ulceration. Ir Med J. 2005 Oct; 98(9):282.
  5. Akbulut, M.; Ozbay, Y.; Karaca, I.; Ilkay, E.; Gundogdu, O., and Arslan, N. The effect of long-term clopidogrel use on neointimal formation after percutaneous coronary intervention. Coron Artery Dis. 2004 Sep; 15(6):347–52.
  6. Akcay, A.; Kanbay, M.; Agca, E.; Sezer, S., and Ozdemir, F. N. Neutropenia due to clopidogrel in a patient with end-stage renal disease. Ann Pharmacother. 2004 Sep; 38(9):1538–9.
  7. Andrawes, W. F.; Bussy, C., and Belmin, J. Prevention of cardiovascular events in elderly people. Drugs Aging. 2005; 22(10):859–76.
  8. Angiolillo, D. J.; Fernandez-Ortiz, A.; Bernardo, E.; Ramirez, C.; Sabate, M.; Jimenez-Quevedo, P.; Hernandez, R.; Moreno, R.; Escaned, J.; Alfonso, F.; Banuelos, C.; Costa, M. A.; Bass, T. A., and Macaya, C. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005 Aug; 54(8):2430–5.
  9. Aronow, W. S. Antiplatelet therapy in peripheral arterial disease. Curr Drug Targets Cardiovasc Haematol Disord. 2004 Sep; 4(3):265–7.
  10. ---. Drug treatment of peripheral arterial disease in the elderly. Drugs Aging. 2006; 23(1):1–12.
  11. ---. Management of peripheral arterial disease. Cardiol Rev. 2005 Mar-2005 Apr 30; 13(2):61–8.
  12. ---. Management of peripheral arterial disease of the lower extremities in elderly patients. J Gerontol A Biol Sci Med Sci. 2004 Feb; 59(2):172–7.
  13. Arsan, S.; Ak, K., and Isbir, S. C. Clopidogrel in coronary artery surgery. Eur J Cardiothorac Surg. 2004 Oct; 26(4):869.
  14. Ascione, R.; Ghosh, A.; Rogers, C. A.; Cohen, A.; Monk, C., and Angelini, G. D. Inhospital patients exposed to clopidogrel before coronary artery bypass graft surgery: a word of caution. Ann Thorac Surg. 2005 Apr; 79(4):1210–6.
  15. Ayala, T. H. and Schulman, S. P. Pathogenesis and early management of non-ST-segment elevation acute coronary syndromes. Cardiol Clin. 2006 Feb; 24(1):19–35.
  16. Bachman, D. S. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology. 2004 Nov 9; 63(9):1761; author reply 1761.
  17. Bahceci, M.; Tuzcu, A.; Akay, F.; Agil, C., and Akay, H. Serious clopidogrel associated renal hematoma in a type 2 diabetic patient with primary hyperparathyroidism after extracorporeal shock wave lithotripsy. Saudi Med J. 2005 Jun; 26(6):1007–9.
  18. Barsky, A. A. and Arora, R. R. Clopidogrel resistance: myth or reality? J Cardiovasc Pharmacol Ther. 2006 Mar; 11(1):47–53.
  19. Bates, E. R.; Lau, W. C., and Bleske, B. E. Loading, pretreatment, and interindividual variability issues with clopidogrel dosing. Circulation. 2005 May 24; 111(20):2557–9.
  20. Baumgartner, I.; Schainfeld, R., and Graziani, L. Management of peripheral vascular disease. Annu Rev Med. 2005; 56:249–72.
  21. Beinart, S. C.; Kolm, P.; Veledar, E.; Zhang, Z.; Mahoney, E. M.; Bouin, O.; Gabriel, S.; Jackson, J.; Chen, R.; Caro, J.; Steinhubl, S.; Topol, E., and Weintraub, W. S. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol. 2005 Sep 6; 46(5):761–9.
  22. Bentley, P. and Sharma, P. Pharmacological treatment of ischemic stroke. Pharmacol Ther. 2005 Dec; 108(3):334–52.
  23. Berger, P. B. Resistance to antiplatelet drugs: is it real or relevant? Catheter Cardiovasc Interv. 2004 May; 62(1):43–5.
  24. Best, P. J.; Mathew, V., and Markovic, S. N. Clopidogrel-associated autoimmune thrombocytopenic purpura. Catheter Cardiovasc Interv. 2004 Jul; 62(3):339–40.
  25. Bezerra, D. C. and Bogousslavsky, J. Antiplatelets in stroke prevention: the MATCH trial. Some answers, many questions and countless perspectives. Cerebrovasc Dis. 2005; 20 Suppl 2:109–18.
  26. Bhatt, D. L. Can clopidogrel and aspirin lower mortality in patients with acute myocardial infarction? Nat Clin Pract Cardiovasc Med. 2006 Apr; 3(4):182–3.
  27. Bhatt, D. L.; Roe, M. T.; Peterson, E. D.; Li, Y.; Chen, A. Y.; Harrington, R. A.; Greenbaum, A. B.; Berger, P. B.; Cannon, C. P.; Cohen, D. J.; Gibson, C. M.; Saucedo, J. F.; Kleiman, N. S.; Hochman, J. S.; Boden, W. E.; Brindis, R. G.; Peacock, W. F.; Smith, S. C. Jr; Pollack, C. V. Jr; Gibler, W. B., and Ohman, E. M. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004 Nov 3; 292(17):2096–104.
  28. Bhatt, D. L. Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American Heart Journal. 148(2):263–8, 2004. 2004.
  29. Billett, H. H. Antiplatelet agents and arterial thrombosis. Clin Geriatr Med. 2006 Feb; 22(1):57–74, viii.
  30. Biondi-Zoccai, G. G.; Agostoni, P.; Sangiorgi, G. M.; Iakovou, I.; Antoniucci, D.; Grube, E.; Tamburino, C.; Di Mario, C.; Reimers, B.; Michev, I.; Goktekin, O.; Airoldi, F.; Chieffo, A.; Cosgrave, J.; Tassanawiwat, W., and Colombo, A. Comparison of ticlopidine vs. clopidogrel in addition to aspirin after paclitaxel-eluting stent implantation: insights from the TRUE (Taxusin Real-life Usage Evaluation) Study. Int J Cardiol. 2006 Apr 14; 108(3):406–7.
  31. Blomkalns, A. L.; Chen, A. Y.; Hochman, J. S.; Peterson, E. D.; Trynosky, K.; Diercks, D. B.; Brogan, G. X. Jr; Boden, W. E.; Roe, M. T.; Ohman, E. M.; Gibler, W. B., and Newby, L. K. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. J Am Coll Cardiol. 2005 Mar 15; 45(6):832–7.
  32. Boden, W. E. Acute coronary syndromes without ST-segment elevation--what is the role of early intervention? N Engl J Med. 2005 Sep 15; 353(11):1159–61.
  33. Boulman, N.; Rozenbaum, M.; Slobodin, G., and Rosner, I. Acute polyarthritis associated with clopidogrel treatment. Isr Med Assoc J. 2005 Oct; 7(10):670–1.
  34. Bulpitt, C. J. Secondary prevention of coronary heart disease in the elderly. Heart. 2005 Mar; 91(3):396–400.
  35. Buresly, K.; Eisenberg, M. J.; Zhang, X., and Pilote, L. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med. 2005 Apr 11; 165(7):784–9.
  36. Burger, W.; Chemnitius, J. M.; Kneissl, G. D., and Rucker, G. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med. 2005 May; 257(5):399–414.
  37. Camara, M. G. and Almeda, F. Q. Clopidogrel (Plavix) desensitization: a case series. Catheter Cardiovasc Interv. 2005 Aug; 65(4):525–7.
  38. Caplan, L. R. Antiplatelet therapy in stroke prevention: present and future. Cerebrovasc Dis. 2006; 21 Suppl 1:1–6.
  39. Carbajal, E. V. and Deedwania, P. Treating non-ST-segment elevation ACS. Pros and cons of current strategies. Postgrad Med. 2005 Sep; 118(3):23–32.
  40. Caro, J. J.; Ishak, K. J., and Migliaccio-Walle, K. Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis. Value Health. 2004 Sep-2004 Oct 31; 7(5):627–35.
  41. Cavendish, J. J.; Cramer, S. C., and Graham, G. D. Role of antiplatelet therapy in cardiovascular disease II: Ischemic stroke. Curr Med Res Opin. 2004 Nov; 20(11):1845–9.
  42. Cavendish, J. J.; Fugit, R. V., and Safani, M. Role of antiplatelet therapy in cardiovascular disease I: Acute coronary syndromes. Curr Med Res Opin. 2004 Nov; 20(11):1839–43.
  43. Cavendish, J. J. and Safani, M. Role of antiplatelet therapy in cardiovascular disease III: Peripheral arterial disease. Curr Med Res Opin. 2004 Nov; 20(11):1851–5.
  44. Cavusoglu, E. The use of clopidogrel in patients with coronary artery disease. Anadolu Kardiyol Derg. 2004 Mar; 4(1):63–72.
  45. Cay, S.; Yilmaz, M. B., and Korkmaz, S. Intracranial bleeding associated with clopidogrel. Cardiovasc Drugs Ther. 2005 Mar; 19(2):157–8.
  46. Chau, T. N.; Yim, K. F.; Mok, N. S.; Chan, W. K.; Leung, V. K.; Leung, M. F., and Lai, S. T. Clopidogrel-induced hepatotoxicity after percutaneous coronary stenting. Hong Kong Med J. 2005 Oct; 11(5):414–6.
  47. Chen, L.; Bracey, A. W.; Radovancevic, R.; Cooper, J. R. Jr; Collard, C. D.; Vaughn, W. K., and Nussmeier, N. A. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2004 Sep; 128(3):425–31.
  48. Chen, Y. G.; Xu, F.; Zhang, Y.; Ji, Q. S.; Sun, Y.; Lu, R. J., and Li, R. J. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chin Med J (Engl). 2006 Jan 5; 119(1):32–6.
  49. Chen, Z. M.; Jiang, L. X.; Chen, Y. P.; Xie, J. X.; Pan, H. C.; Peto, R.; Collins, R., and Liu, L. S. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005 Nov 5; 366(9497):1607–21.
  50. Chong, J. Y. and Mohr, J. P. Anticoagulation and platelet antiaggregation therapy in stroke prevention. Curr Opin Neurol. 2005 Feb; 18(1):53–7.
  51. Chu, M. W.; Wilson, S. R.; Novick, R. J.; Stitt, L. W., and Quantz, M. A. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg. 2004 Nov; 78(5):1536–41.
  52. Cohen, M. Predictors of bleeding risk and long-term mortality in patients with acute coronary syndromes. Curr Med Res Opin. 2005 Mar; 21(3):439–45.
  53. Cohen, S. N. Preventing recurrent ischemic stroke: a 3-step plan. J Fam Pract. 2005 May; 54(5):412–22.
  54. Colwell, J. A. Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus. Am J Cardiovasc Drugs. 2004; 4(2):87–106.
  55. Comerota, A. J. Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination. Atheroscler Suppl. 2005 Dec 15; 6(4):13–9.
  56. Connors, J. J. 3rd. Pharmacologic agents in stroke prevention, acute stroke therapy, and interventional procedures. J Vasc Interv Radiol. 2004 Jan; 15(1 Pt 2):S87–101.
  57. Cowper, P. A.; Udayakumar, K.; Sketch, M. H. Jr, and Peterson, E. D. Economic effects of prolonged clopidogrel therapy after percutaneous coronary intervention. J Am Coll Cardiol. 2005 Feb 1; 45(3):369–76.
  58. Daskalopoulou, S. S.; Stansby, G., and Mikhailidis, D. P. Clopidogrel and vascular disease prevention. Curr Med Res Opin. 2004 Nov; 20(11):1835–8.
  59. Diener, H. C. Is clopidogrel the antiplatelet drug of choice for high-risk patients with stroke/TIA?: Yes. J Thromb Haemost. 2005 Jun; 3(6):1133–6.
  60. Diener, H. C.; Ringleb, P. A., and Savi, P. Clopidogrel for the secondary prevention of stroke. Expert Opin Pharmacother. 2005 May; 6(5):755–64.
  61. Doggrell, S. A. CLARITY about the use of clopidogrel in patients with acute coronary syndromes and myocardial infarction. Expert Opin Pharmacother. 2005 Aug; 6(10):1761–4.
  62. Doogue, M. P.; Begg, E. J., and Bridgman, P. Clopidogrel hypersensitivity syndrome with rash, fever, and neutropenia. Mayo Clin Proc. 2005 Oct; 80(10):1368–70.
  63. Douglas, J. S. Jr. Role of adjunct pharmacologic therapy in the era of drug-eluting stents. Atheroscler Suppl. 2005 Dec 15; 6(4):47–52.
  64. Duffy, B. and Bhatt, D. L. Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much? Am J Cardiovasc Drugs. 2005; 5(5):307–18.
  65. Dziewierz, A.; Dudek, D.; Heba, G.; Rakowski, T.; Mielecki, W., and Dubiel, J. S. Inter-individual variability in response to clopidogrel in patients with coronary artery disease. Kardiol Pol. 2005 Feb; 62(2):108-17; discussion 118.
  66. Elkind, M. S. Secondary stroke prevention: review of clinical trials. Clin Cardiol. 2004 May; 27(5 Suppl 2):II25–35.
  67. Elsasser, A.; Nef, H.; Mollmann, H., and Hamm, C. W. Clopidogrel in acute coronary syndrome: when, how much, how long? Z Kardiol. 2005 Jun; 94(6):377–82.
  68. Eriksson, P. Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the "Emperor's New Clothes" revisited. Eur Heart J. 2004 May; 25(9):720–2.
  69. Fahey, C. D.; Alberts, M. J., and Bernstein, R. A. Oral clopidogrel load in aspirin-resistant capsular warning syndrome. Neurocrit Care. 2005; 2(2):183–4.
  70. Felmeden, D. C. and Lip, G. Y. Antithrombotic therapy in hypertension: a Cochrane Systematic review. J Hum Hypertens. 2005 Mar; 19(3):185–96.
  71. Ferraris, V. A.; Ferraris, S. P.; Moliterno, D. J.; Camp, P.; Walenga, J. M.; Messmore, H. L.; Jeske, W. P.; Edwards, F. H.; Royston, D.; Shahian, D. M.; Peterson, E.; Bridges, C. R., and Despotis, G. The Society of Thoracic Surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization (executive summary). Ann Thorac Surg. 2005 Apr; 79(4):1454–61.
  72. Fisher, M. Results of the management of atherothrombosis with clopidogrel in high-risk patients trial: implications for the neurologist. Arch Neurol. 2006 Jan; 63(1):20–4.
  73. Fleck, J. D. Antiplatelet medications in the secondary prevention of ischemic stroke. Curr Neurol Neurosci Rep. 2005 Feb; 5(1):1–3.
  74. Fox, K. A. Management of acute coronary syndromes: an update. Heart. 2004 Jun; 90(6):698–706.
  75. Frelinger, A. L. 3rd and Michelson, A. D. Clopidogrel linking evaluation of platelet response variability to mechanism of action. J Am Coll Cardiol. 2005 Aug 16; 46(4):646–7.
  76. Gaspoz, J. M. and de Moerloose, P. Aspirin or clopidogrel for secondary prevention of cardiovascular events: is there a winner? Am J Med. 2004 Jun 15; 116(12):850–2.
  77. Gebel, J. M. Jr. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view. J Am Coll Cardiol. 2005 Sep 6; 46(5):752–5.
  78. Gibbons, R. J. and Fuster, V. Therapy for patients with acute coronary syndromes--new opportunities. N Engl J Med. 2006 Apr 6; 354(14):1524–7.
  79. Giles, M. F. and Rothwell, P. M. Prediction and prevention of stroke after transient ischemic attack in the short and long term. Expert Rev Neurother. 2006 Mar; 6(3):381–95.
  80. Gill, S. S. Bleeding complications in elderly patients following acute myocardial infarction. Arch Intern Med. 2005 Nov 14; 165(20):2430–1.
  81. Gluckman, T. J.; Rade, J. J., and Schulman, S. P. The value of clopidogrel administered postoperatively following a non-ST-segment elevation acute coronary syndrome. Chest. 2005 Jun; 127(6):2297.
  82. Gowda, R. M.; Misra, D., and Khan, I. A. Hypersensitivity skin rash: an adverse drug reaction to clopidogrel loading dose. Int J Cardiol. 2004 Jun; 95(2–3):333.
  83. Griffin, G. Antiplatelet therapy and anticoagulation in patients with hypertension. Am Fam Physician. 2005 Mar 1; 71(5):897–9.
  84. Grossmann, R.; Sokolova, O.; Schnurr, A.; Bonz, A.; Porsche, C.; Obergfell, A.; Lengenfelder, B.; Walter, U., and Eigenthaler, M. Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thromb Haemost. 2004 Dec; 92(6):1201–6.
  85. Gupta, R. and Krieger, D. W. Preventing ischemic stroke: choosing the best strategy. Cleve Clin J Med. 2005 May; 72(5):433–44.
  86. Gurbel, P. A.; Bliden, K. P.; Samara, W.; Yoho, J. A.; Hayes, K.; Fissha, M. Z., and Tantry, U. S. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol. 2005 Nov 15; 46(10):1827–32.
  87. Guthikonda, S.; Lev, E. I., and Kleiman, N. S. Resistance to antiplatelet therapy. Curr Cardiol Rep. 2005 Jul; 7(4):242–8.
  88. Hackam, D. G.; Goodman, S. G., and Anand, S. S. Management of risk in peripheral artery disease: recent therapeutic advances. Am Heart J. 2005 Jul; 150(1):35–40.
  89. Halkos, M. E.; Cooper, W. A.; Petersen, R.; Puskas, J. D.; Lattouf, O. M.; Craver, J. M., and Guyton, R. A. Early administration of clopidogrel is safe after off-pump coronary artery bypass surgery. Ann Thorac Surg. 2006 Mar; 81(3):815–9.
  90. Hankey, G. J. Is clopidogrel the antiplatelet drug of choice for high-risk patients with stroke/TIA?: No. J Thromb Haemost. 2005 Jun; 3(6):1137–40.
  91. ---. Preventable stroke and stroke prevention. J Thromb Haemost. 2005 Aug; 3(8):1638–45.
  92. ---. Review: dipyridamole given with or without aspirin reduces recurrent stroke. ACP J Club. 2005 Jul-2005 Aug 31; 143(1):10.
  93. ---. Secondary prevention of recurrent stroke. Stroke. 2005 Feb; 36(2):218–21.
  94. Hankey, G. J. and Eikelboom, J. W. Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks. Neurology. 2005 Apr 12; 64(7):1117–21.
  95. Hankey, G. J.; Norman, P. E., and Eikelboom, J. W. Medical treatment of peripheral arterial disease. JAMA. 2006 Feb 1; 295(5):547–53.
  96. Heestermans, A. A.; van Werkum, J. W.; Schomig, E.; ten Berg, J. M., and Taubert, D. Clopidogrel resistance caused by a failure to metabolize clopidogrel into its metabolites. J Thromb Haemost. 2006 May; 4(5):1143–5.
  97. Hiatt, W. R. and Krantz, M. J. Masterclass series in peripheral arterial disease. Antiplatelet therapy for peripheral arterial disease and claudication. Vasc Med. 2006 Feb; 11(1):55–60.
  98. Hirsh, J. and Bhatt, D. L. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med. 2004 Oct 25; 164(19):2106–10.
  99. Jamieson, D. G.; Parekh, A., and Ezekowitz, M. D. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents. J Cardiovasc Pharmacol Ther. 2005 Sep; 10(3):153–61.
  100. John, J. M. and Bhatt, D. L. Management of acute coronary syndrome in diabetes mellitus. Herz. 2004 Aug; 29(5):532–41.
  101. Kadakia, R. A. and Ferguson, J. J. Optimal antithrombotic treatment for percutaneous coronary intervention. Minerva Cardioangiol. 2005 Feb; 53(1):15–42.
  102. Kandzari, D. E. Current concepts in the antithrombotic management of non-ST-elevation acute coronary syndromes. Curr Cardiol Rep. 2004 Jul; 6(4):279–86.
  103. Kandzari, D. E.; Berger, P. B.; Kastrati, A.; Steinhubl, S. R.; Mehilli, J.; Dotzer, F.; Ten Berg, J. M.; Neumann, F. J.; Bollwein, H.; Dirschinger, J., and Schomig, A. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol. 2004 Dec 7; 44(11):2133–6.
  104. Kannan, S. Molecular mechanism of Clopidogrel and Aspirin therapy-induced bleeding episodes. Med Hypotheses. 2006; 66(1):202–3.
  105. Karnon, J.; Brennan, A.; Pandor, A.; Fowkes, G.; Lee, A.; Gray, D.; Coshall, C.; Nicholls, C., and Akehurst, R. Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK. Curr Med Res Opin. 2005 Jan; 21(1):101–12.
  106. Kastrati, A.; Mehilli, J.; von Beckerath, N.; Dibra, A.; Hausleiter, J.; Pache, J.; Schuhlen, H.; Schmitt, C.; Dirschinger, J., and Schomig, A. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA. 2005 Jan 12; 293(2):165–71.
  107. Kastrati, A.; von Beckerath, N.; Joost, A.; Pogatsa-Murray, G.; Gorchakova, O., and Schomig, A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation. 2004 Oct 5; 110(14):1916–9.
  108. Kenner, M. E. and Kelley, R. E. Update on stroke prevention. Compr Ther. 2005 Summer; 31(2):113–8.
  109. Kerr, J. L.; Oppelt, T. F., and Rowen, R. C. Role of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practice. Pharmacotherapy. 2004 Aug; 24(8):1037–49.
  110. Kirshner, H. S.; Biller, J., and Callahan, A. S. 3rd. Long-term therapy to prevent stroke. J Am Board Fam Pract. 2005 Nov-2005 Dec 31; 18(6):528–40.
  111. Koennecke, H. C. Secondary prevention of stroke: a practical guide to drug treatment. CNS Drugs. 2004; 18(4):221–41.
  112. Koh, T. W. Long-term clopidogrel therapy in the drug-eluting stent era: beyond CREDO and PCI-CURE. Eur Heart J. 2004 Aug; 25(15):1364; author reply 1364–5.
  113. Kubler, P. A.; Pillans, P. I.; Marrinan, M. C., and Frogley, M. Concordance between clopidogrel use and prescribing guidelines. Intern Med J. 2004 Dec; 34(12):663–7.
  114. Kumana, C. R.; Cheung, G.; Lauder, I. J., and Cheung, B. M. Long-term combination therapy with aspirin and clopidogrel. J Cardiovasc Pharmacol Ther. 2004 Dec; 9(4):223–5.
  115. Lamotte, M.; Annemans, L.; Evers, T., and Kubin, M. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. Pharmacoeconomics. 2006; 24(2):155–69.
  116. Lange, R. A. and Hillis, L. D. Antiplatelet therapy for ischemic heart disease. N Engl J Med. 2004 Jan 15; 350(3):277–80.
  117. Lee, S. W.; Park, S. W.; Hong, M. K.; Kim, Y. H.; Lee, B. K.; Song, J. M.; Han, K. H.; Lee, C. W.; Kang, D. H.; Song, J. K.; Kim, J. J., and Park, S. J. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol. 2005 Nov 15; 46(10):1833–7.
  118. Lenzen, M. J.; Boersma, E.; Bertrand, M. E.; Maier, W.; Moris, C.; Piscione, F.; Sechtem, U.; Stahle, E.; Widimsky, P.; de Jaegere, P.; Scholte op Reimer, W. J.; Mercado, N., and Wijns, W. Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization. Eur Heart J. 2005 Jun; 26(12):1169–79.
  119. Leonardi-Bee, J.; Bath, P. M.; Bousser, M. G.; Davalos, A.; Diener, H. C.; Guiraud-Chaumeil, B.; Sivenius, J.; Yatsu, F., and Dewey, M. E. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke. 2005 Jan; 36(1):162–8.
  120. Leong, J. Y.; Baker, R. A.; Shah, P. J.; Cherian, V. K., and Knight, J. L. Clopidogrel and bleeding after coronary artery bypass graft surgery. Ann Thorac Surg. 2005 Sep; 80(3):928–33.
  121. Leopold, J. A. and Antman, E. M. Dual antiplatelet therapy for coronary stenting: a clear path for a research agenda. Circulation. 2005 Mar 8; 111(9):1097–9.
  122. Lewis, B. S.; Mehta, S. R.; Fox, K. A.; Halon, D. A.; Zhao, F.; Peters, R. J.; Keltai, M.; Budaj, A., and Yusuf, S. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Am Heart J. 2005 Dec; 150(6):1177–84.
  123. Lewis, S. C. and Warlow, C. P. There is no evidence that the benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke. 2004 Oct; 35(10):2241.
  124. Liberopoulos, E. N.; Elisaf, M. S.; Tselepis, A. D.; Archimandritis, A.; Kiskinis, D.; Cokkinos, D., and Mikhailidis, D. P. Upper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: where we are now? Platelets. 2006 Feb; 17(1):1–6.
  125. Lim, E.; Cornelissen, J.; Routledge, T.; Kirtland, S.; Charman, S. C.; Bellm, S.; Munday, H.; Khan, O.; Masood, I., and Large, S. Clopidogrel did not inhibit platelet function early after coronary bypass surgery: A prospective randomized trial. J Thorac Cardiovasc Surg. 2004 Sep; 128(3):432–5.
  126. Lim, M. J.; Eagle, K. A.; Gore, J. M.; Anderson, F. A. Jr; Dabbous, O. H.; Mehta, R. H.; Granger, C. B.; Fox, K. A.; Spencer, F. A., and Goldberg, R. J. Treating patients with acute coronary syndromes with aggressive antiplatelet therapy (from the Global Registry of Acute Coronary Events). Am J Cardiol. 2005 Oct 1; 96(7):917–21.
  127. Lim, M. J.; Spencer, F. A.; Gore, J. M.; Dabbous, O. H.; Agnelli, G.; Kline-Rogers, E. M.; Dibenedetto, D.; Eagle, K. A., and Mehta, R. H. Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. Eur Heart J. 2005 Jun; 26(11):1063–9.
  128. Lindgren, A.; Husted, S.; Staaf, G., and Ziegler, B. Dipyridamole and headache--a pilot study of initial dose titration. J Neurol Sci. 2004 Aug 30; 223(2):179–84.
  129. Lindgren, P.; Stenestrand, U.; Malmberg, K., and Jonsson, B. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden. Clin Ther. 2005 Jan; 27(1):100–10.
  130. Lipsitz, E. C. and Kim, S. Antithrombotic therapy in peripheral arterial disease. Clin Geriatr Med. 2006 Feb; 22(1):183–98, x.
  131. Lumsden, A. B. and Rice, T. W. Medical management of peripheral arterial disease: a therapeutic algorithm. J Endovasc Ther. 2006 Feb; 13 Suppl 2:II19–29.
  132. Mahoney, E. M.; Mehta, S.; Yuan, Y.; Jackson, J.; Chen, R.; Gabriel, S.; Lamy, A.; Culler, S.; Caro, J.; Yusuf, S., and Weintraub, W. S. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am Heart J. 2006 Jan; 151(1):219–27.
  133. Manolis, A. S.; Tzeis, S.; Andrikopoulos, G.; Koulouris, S., and Melita, H. Aspirin and clopidogrel: a sweeping combination in cardiology. Curr Med Chem Cardiovasc Hematol Agents. 2005 Jul; 3(3):203–19.
  134. Manor, S. M.; Guillory, G. S., and Jain, S. P. Clopidogrel-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after coronary artery stenting. Pharmacotherapy. 2004 May; 24(5):664–7.
  135. Matchar, D. B.; Samsa, G. P., and Liu, S. Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty. Value Health. 2005 Sep-2005 Oct 31; 8(5):572–80.
  136. McCollam, P. and Etemad, L. Cost of care for new-onset acute coronary syndrome patients who undergo coronary revascularization. J Invasive Cardiol. 2005 Jun; 17(6):307–11.
  137. McKevitt, F. M.; Randall, M. S.; Cleveland, T. J.; Gaines, P. A.; Tan, K. T., and Venables, G. S. The benefits of combined anti-platelet treatment in carotid artery stenting. Eur J Vasc Endovasc Surg. 2005 May; 29(5):522–7.
  138. Micieli, G. and Cavallini, A. New therapeutic strategies with antiplatelet agents. Neurol Sci. 2004 Mar; 25 Suppl 1:S13–5.
  139. Mitsios, J. V.; Papathanasiou, A. I.; Elisaf, M.; Goudevenos, J. A., and Tselepis, A. D. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes. Platelets. 2005 Aug; 16(5):287–92.
  140. Moses, J. W. and Shah, P. K. Enhanced long-term antiplatelet therapy after coronary stenting. J Invasive Cardiol. 2005 Dec; 17(12):669–76.
  141. Moussouttas, M. Emerging therapies: clopidogrel and aspirin. Stroke. 2005 Apr; 36(4):707.
  142. Moussouttas, M. and Papamitsakis, N. Combination antiplatelet agents in ischemic cerebrovascular disease. Mt Sinai J Med. 2005 Jan; 72(1):16–22.
  143. Mukherjee, D. and Bates, E. R. Current role of antithrombotic agents in the treatment of acute coronary syndromes. Semin Thromb Hemost. 2004 Dec; 30(6):627–32.
  144. Mukherjee, D.; Fang, J.; Chetcuti, S.; Moscucci, M.; Kline-Rogers, E., and Eagle, K. A. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation. 2004 Feb 17; 109(6):745–9.
  145. Mukherjee, D.; Topol, E. J.; Moliterno, D. J.; Brennan, D. M.; Ziada, K.; Cho, L., and Steinhubl, S. R. Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment. Heart. 2006 Jan; 92(1):49–51.
  146. Ness, J.; Aronow, W. S.; Newkirk, E., and McDanel, D. Prevalence of symptomatic peripheral arterial disease, modifiable risk factors, and appropriate use of drugs in the treatment of peripheral arterial disease in older persons seen in a university general medicine clinic. J Gerontol A Biol Sci Med Sci. 2005 Feb; 60(2):255–7.
  147. Nguyen, T. A.; Diodati, J. G., and Pharand, C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005 Apr 19; 45(8):1157–64.
  148. Nikolsky, E. and Dangas, G. Clopidogrel loading dose pre-PCI: how high? J Invasive Cardiol. 2004 Sep; 16(9):551–2.
  149. Norman, P. E.; Eikelboom, J. W., and Hankey, G. J. Peripheral arterial disease: prognostic significance and prevention of atherothrombotic complications. Med J Aust. 2004 Aug 2; 181(3):150–4.
  150. Norris, J. W. Antiplatelet agents in secondary prevention of stroke: a perspective. Stroke. 2005 Sep; 36(9):2034–6.
  151. O'Donoghue, M. and Sabatine, M. S. Appropriate invasive and conservative treatment approaches for patients with ST-elevation MI. Curr Treat Options Cardiovasc Med. 2006 Feb; 8(1):3–11.
  152. Ocava, L. C.; Singh, M.; Malhotra, S., and Rosenbaum, D. M. Antithrombotic and thrombolytic therapy for ischemic stroke. Clin Geriatr Med. 2006 Feb; 22(1):135–54, ix–x.
  153. Ohman, E. M.; Roe, M. T.; Smith, S. C. Jr; Brindis, R. G.; Christenson, R. H.; Harrington, R. A.; Gibler, W. B., and Peterson, E. D. Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative. Am Heart J. 2004 Nov; 148(5 Suppl):S34–9.
  154. Orford, J. L.; Fasseas, P.; Melby, S.; Burger, K.; Steinhubl, S. R.; Holmes, D. R., and Berger, P. B. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J. 2004 Mar; 147(3):463–7.
  155. Paraskevas, K. I.; Daskalopoulou, S. S.; Daskalopoulos, M. E., and Liapis, C. D. Secondary prevention of ischemic cerebrovascular disease. What is the evidence? Angiology. 2005 Sep-2005 Oct 31; 56(5):539–52.
  156. Parodi, G.; Sciagra, R.; Migliorini, A.; Memisha, G.; Moschi, G.; Valenti, R.; Pupi, A., and Antoniucci, D. A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy. Am Heart J. 2005 Aug; 150(2):220.
  157. Patrono, C.; Bachmann, F.; Baigent, C.; Bode, C.; De Caterina, R.; Charbonnier, B.; Fitzgerald, D.; Hirsh, J.; Husted, S.; Kvasnicka, J.; Montalescot, G.; Garcia Rodriguez, L. A.; Verheugt, F.; Vermylen, J.; Wallentin, L.; Priori, S. G.; Alonso Garcia, M. A.; Blanc, J. J.; Budaj, A.; Cowie, M.; Dean, V.; Deckers, J.; Fernandez Burgos, E.; Lekakis, J.; Lindahl, B.; Mazzotta, G.; Morais, J.; Oto, A.; Smiseth, O. A.; Morais, J.; Deckers, J.; Ferreira, R.; Mazzotta, G.; Steg, P. G.; Teixeira, F., and Wilcox, R. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J. 2004 Jan; 25(2):166–81.
  158. Phillips, R. A. Secondary stroke: new horizons in prevention. Clin Cardiol. 2004 May; 27(5 Suppl 2):II1–3.
  159. Piechowski-Jozwiak, B.; Maulaz, A., and Bogousslavsky, J. Secondary prevention of stroke with antiplatelet agents in patients with diabetes mellitus. Cerebrovasc Dis. 2005; 20 Suppl 1:15–23.
  160. Pongracz, E. and Kaposzta, Z. Antiplatelet therapy in ischemic stroke. Expert Rev Neurother. 2005 Jul; 5(4):541–9.
  161. Poulsen, T. S.; Vinholt, P.; Mickley, H.; Korsholm, L.; Kristensen, S. R., and Damkier, P. Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors? Re-evaluating the evidence. Basic Clin Pharmacol Toxicol. 2005 Feb; 96(2):103–10.
  162. Rabadi, M. H. and Blass, J. Randomized clinical stroke trials in 2004. Curr Atheroscler Rep. 2005 Jul; 7(4):319–25.
  163. Rajagopal, V. and Bhatt, D. L. Controversies of oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. Semin Thromb Hemost. 2004 Dec; 30(6):649–55.
  164. Rantanen, K. and Tatlisumak, T. Secondary prevention of ischemic stroke. Curr Drug Targets. 2004 Jul; 5(5):457–72.
  165. Reid, J.; MacLeod, M. J., and Williams, D. Timing of aspirin and secondary preventative therapies in acute stroke: support for use of stroke units. Scott Med J. 2005 May; 50(2):69–72.
  166. Ringborg, A.; Lindgren, P., and Jonsson, B. The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. Eur J Health Econ. 2005 Dec; 6(4):354–6, 358–62.
  167. Ringleb, P. A.; Schwark, C.; Schwaninger, M., and Schellinger, P. D. Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke. Expert Opin Pharmacother. 2005 Mar; 6(3):359–67.
  168. Robinson, M.; Palmer, S.; Sculpher, M.; Philips, Z.; Ginnelly, L.; Bowens, A.; Golder, S.; Alfakih, K.; Bakhai, A.; Packham, C.; Cooper, N.; Abrams, K.; Eastwood, A.; Pearman, A.; Flather, M.; Gray, D., and Hall, A. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling. Health Technol Assess. 2005 Jul; 9(27):iii–iv, ix–xi, 1–158.
  169. Rocca, B. and Patrono, C. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost. 2005 Aug; 3(8):1597–602.
  170. Roquer, J.; Rodriguez Campello, A.; Gomis, M.; Ois, A.; Puente, V., and Munteis, E. Previous antiplatelet therapy is an independent predictor of 30-day mortality after spontaneous supratentorial intracerebral hemorrhage. J Neurol. 2005 Apr; 252(4):412–6.
  171. Rothwell, P. M.; Buchan, A., and Johnston, S. C. Recent advances in management of transient ischaemic attacks and minor ischaemic strokes. Lancet Neurol. 2006 Apr; 5(4):323–31.
  172. Rubboli, A.; Milandri, M.; Castelvetri, C., and Cosmi, B. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Cardiology. 2005; 104(2):101–6.
  173. Ryan, J. W.; Peterson, E. D.; Chen, A. Y.; Roe, M. T.; Ohman, E. M.; Cannon, C. P.; Berger, P. B.; Saucedo, J. F.; DeLong, E. R.; Normand, S. L.; Pollack, C. V. Jr, and Cohen, D. J. Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Registry. Circulation. 2005 Nov 15; 112(20):3049–57.
  174. Sabatine, M. S.; Cannon, C. P.; Gibson, C. M.; Lopez-Sendon, J. L.; Montalescot, G.; Theroux, P.; Lewis, B. S.; Murphy, S. A.; McCabe, C. H., and Braunwald, E. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005 Sep 14; 294(10):1224–32.
  175. Salam, A. M. and Al Suwaidi, J. Evolving role of clopidogrel in acute coronary syndromes. Expert Rev Cardiovasc Ther. 2005 Nov; 3(6):977–80.
  176. Saleem, M. A.; Aronow, W. S.; Ravipati, G.; Moorthy, C. R.; Singh, S.; Agarwal, N.; Monsen, C. E., and Pucillo, A. L. Intracoronary brachytherapy for treatment of in-stent restenosis. Cardiol Rev. 2005 May-2005 Jun 30; 13(3):139–41.
  177. Samara, W. M.; Bliden, K. P.; Tantry, U. S., and Gurbel, P. A. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res. 2005; 115(1–2):89–94.
  178. Savi, P. and Herbert, J. M. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost. 2005 Apr; 31(2):174–83.
  179. Schleinitz, M. D. and Heidenreich, P. A. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med. 2005 Feb 15; 142(4):251–9.
  180. Schleinitz, M. D.; Weiss, J. P., and Owens, D. K. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis. Am J Med. 2004 Jun 15; 116(12):797–806.
  181. Schneck, M. J. and Biller, J. Antithrombotic therapy for prevention of recurrent stroke in the new millennium. Expert Rev Neurother. 2004 Mar; 4(2):145–9.
  182. Schror, K.; Weber, A. A., and Hohlfeld, T. Clopidogrel "resistance". Thromb Haemost. 2004 Aug; 92(2):229–31.
  183. Scirica, B. M. and Morrow, D. A. Appropriate invasive and conservative treatment approaches for patients with non-ST-elevation MI. Curr Treat Options Cardiovasc Med. 2006 Feb; 8(1):13–21.
  184. Segev, A.; Strauss, B. H.; Tan, M.; Constance, C.; Langer, A., and Goodman, S. G. Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries. Am Heart J. 2005 Oct; 150(4):690–4.
  185. Serebruany, V.; Malinin, A.; Ziai, W.; Atar, D.; Pokov, A.; Jilma, B., and Hanley, D. Dipyridamole decreases protease-activated receptor and annexin-v binding on platelets of post stroke patients with aspirin nonresponsiveness. Cerebrovasc Dis. 2006; 21(1–2):98–105.
  186. Shammas, N. W. and Dippel, E. J. Evidence-based management of peripheral vascular disease. Curr Atheroscler Rep. 2005 Sep; 7(5):358–63.
  187. Sibon, I. and Orgogozo, J. M. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology. 2004 Apr 13; 62(7):1187–9.
  188. Simonson, W. and Beizer, J. L. Antiplatelet therapy for secondary prevention of the complications of atherothrombotic disease. Consult Pharm. 2004 Sep; 19(9):813–23.
  189. Smout, J. D.; Mikhailidis, D. P.; Shenton, B. K., and Stansby, G. Combination antiplatelet therapy in patients with peripheral vascular bypass grafts. Clin Appl Thromb Hemost. 2004 Jan; 10(1):9–18.
  190. Stavropoulos, S. W. and Shlansky-Goldberg, R. D. Use of antiplatelet inhibitors in peripheral vascular interventions. Seminars in Interventional Radiology. 2005; 22(2):80–87.
  191. Steimle, A. E. Antiplatelet therapy for ischemic heart disease. N Engl J Med. 2004 May 13; 350(20):2101–2; author reply 2101–2.
  192. Steinhubl, S. R. and Charnigo, R. Clopidogrel treatment prior to percutaneous coronary intervention: when enough isn't enough. JAMA. 2006 Apr 5; 295(13):1581–2.
  193. Steinhubl, S. R. and Topol, E. J. Risk reduction with long-term clopidogrel following percutaneous coronary intervention. Eur Heart J. 2004 Dec; 25(23):2169–70; author reply 2170–1.
  194. Stone, G. W. and Aronow, H. D. Long-term care after percutaneous coronary intervention: focus on the role of antiplatelet therapy. Mayo Clin Proc. 2006 May; 81(5):641–52.
  195. Strecker, E. P.; Boos, I. B.; Gottmann, D., and Vetter, S. Clopidogrel plus long-term aspirin after femoro-popliteal stenting. The CLAFS project: 1- and 2-year results. Eur Radiol. 2004 Feb; 14(2):302–8.
  196. Sudlow, C. What is the role of dipyridamole in long-term secondary prevention after an ischemic stroke or transient ischemic attack? CMAJ. 2005 Oct 25; 173(9):1024–6.
  197. Taher, T. H.; Stang, L.; Gordon, P. A., and Armstrong, P. W. Clopidogrel does not induce fibrinolysis in healthy subjects. Thromb Res. 2004; 114(2):97–100.
  198. Takikawa, H. Lessons from ticlopidine-induced liver injury. Hepatol Res. 2005 Aug 19.
  199. Tanaka, K. A.; Szlam, F.; Kelly, A. B.; Vega, J. D., and Levy, J. H. Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding. Platelets. 2004 Aug; 15(5):325–32.
  200. Tantry, U. S.; Bliden, K. P., and Gurbel, P. A. Resistance to antiplatelet drugs: current status and future research. Expert Opin Pharmacother. 2005 Oct; 6(12):2027–45.
  201. ---. What is the best measure of thrombotic risks--pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation? Catheter Cardiovasc Interv. 2005 Dec; 66(4):597–8.
  202. Teal, P. A. Recent clinical trial results with antiplatelet therapy: implications in stroke prevention. Cerebrovasc Dis. 2004; 17 Suppl 3:6–10.
  203. Tei, H.; Uchiyama, S., and Usui, T. Predictors of good prognosis in total anterior circulation infarction within 6 h after onset under conventional therapy. Acta Neurol Scand. 2006 May; 113(5):301–6.
  204. Templin, C.; Schaefer, A.; Stumme, B.; Drexler, H., and von Depka, M. Combined aspirin and Clopidogrel resistance associated with recurrent coronary stent thrombosis. Clin Res Cardiol. 2006 Feb; 95(2):122–6.
  205. Toyoda, K.; Okada, Y.; Minematsu, K.; Kamouchi, M.; Fujimoto, S.; Ibayashi, S., and Inoue, T. Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. Neurology. 2005 Oct 11; 65(7):1000–4.
  206. Tran, H. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Vasc Med. 2004 Feb; 9(1):90.
  207. Uchiyama, S.; Nakamura, T.; Yamazaki, M.; Kimura, Y., and Iwata, M. New modalities and aspects of antiplatelet therapy for stroke prevention. Cerebrovasc Dis. 2006; 21 Suppl 1:7–16.
  208. Vats, H. S.; Hocking, W. G., and Rezkalla, S. H. Suspected clopidogrel resistance in a patient with acute stent thrombosis. Nat Clin Pract Cardiovasc Med. 2006 Apr; 3(4):226–30; quiz 232.
  209. Verma, V. K. and Hollenberg, S. M. Update on acute coronary syndromes and ST-elevation myocardial infarction. Curr Opin Crit Care. 2005 Oct; 11(5):401–5.
  210. Vikman, S.; Airaksinen, K. E.; Tierala, I.; Peuhkurinen, K.; Majamaa-Voltti, K.; Niemela, M.; Tuunanen, H.; Nieminen, M. S., and Niemela, K. Improved adherence to practice guidelines yields better outcome in high-risk patients with acute coronary syndrome without ST elevation: findings from nationwide FINACS studies. J Intern Med. 2004 Oct; 256(4):316–23.
  211. Volturo, G. A.; Mazzola, J. L., and Przylenk, K. The role of antiplatelet therapy in the management of acute coronary syndromes. Expert Opin Drug Saf. 2005 May; 4(3):541–56.
  212. von Beckerath, N.; Taubert, D.; Pogatsa-Murray, G.; Wieczorek, A.; Schomig, E.; Schomig, A., and Kastrati, A. A patient with stent thrombosis, clopidogrel-resistance and failure to metabolize clopidogrel to its active metabolite. Thromb Haemost. 2005 Apr; 93(4):789–91.
  213. Wahidi, M. M.; Garland, R.; Feller-Kopman, D.; Herth, F.; Becker, H. D., and Ernst, A. Effect of clopidogrel with and without aspirin on bleeding following transbronchial lung biopsy. Chest. 2005 Mar; 127(3):961–4.
  214. Wallentin, L. Prevention of cardiovascular events after acute coronary syndrome. Semin Vasc Med. 2005 Aug; 5(3):293–300.
  215. Walsh, S. J.; Spence, M. S.; Crossman, D., and Adgey, A. A. Clopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond. Heart. 2005 Sep; 91(9):1135–40.
  216. Wang, T. H.; Bhatt, D. L., and Topol, E. J. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J. 2006 Mar; 27(6):647–54.
  217. Wang, Y.; Wu, D.; Wang, Y.; Ma, R.; Wang, C., and Zhao, W. A survey on adherence to secondary ischemic stroke prevention. Neurol Res. 2006 Jan; 28(1):16–20.
  218. Wani, M.; Nga, E., and Navaratnasingham, R. Should a patient with primary intracerebral haemorrhage receive antiplatelet or anticoagulant therapy? BMJ. 2005 Aug 20; 331(7514):439–42.
  219. Wassef, W. and Rullan, R. Interventional endoscopy. Curr Opin Gastroenterol. 2005 Nov; 21(6):644–52.
  220. Waters, R. E.; Kandzari, D. E.; Phillips, H. R.; Crawford, L. E., and Sketch, M. H. Jr. Late thrombosis following treatment of in-stent restenosis with drug-eluting stents after discontinuation of antiplatelet therapy. Catheter Cardiovasc Interv. 2005 Aug; 65(4):520–4.
  221. Weimar, C. and Diener, H. C. What's new in stroke prevention and treatment. Expert Rev Neurother. 2006 Feb; 6(2):185–93.
  222. Weinberger, J. Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke. Drugs. 2005; 65(4):461–71.
  223. Weintraub, W.; Jonsson, B., and Bertrand, M. The value of clopidogrel in addition to standard therapy in reducing atherothrombotic events. Pharmacoeconomics. 2004; 22 Suppl 4:29–41.
  224. Weintraub, W. S.; Mahoney, E. M.; Lamy, A.; Culler, S.; Yuan, Y.; Caro, J.; Gabriel, S., and Yusuf, S. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol. 2005 Mar 15; 45(6):838–45.
  225. Weir, N. U.; Demchuk, A. M.; Buchan, A. M., and Hill, M. D. Stroke prevention. MATCHing therapy to the patient with TIA. Postgrad Med. 2005 Jan; 117(1):26–30.
  226. Wenger, N. K.; Helmy, T.; Patel, A. D., and Lerakis, S. Evidence-based management of coronary artery disease in the elderly--current perspectives. MedGenMed. 2005; 7(2):75.
  227. Weyrich, A. S.; Denis, M. M.; Kuhlmann-Eyre, J. R.; Spencer, E. D.; Dixon, D. A.; Marathe, G. K.; McIntyre, T. M.; Zimmerman, G. A., and Prescott, S. M. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation. 2005 Feb 8; 111(5):633–42.
  228. Wolak, A.; Amit, G.; Cafri, C.; Gilutz, H.; Ilia, R., and Zahger, D. Increased long term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation. Int J Cardiol. 2005 Sep 1; 103(3):293–7.
  229. Wolfram, R. M.; Torguson, R. L.; Hassani, S. E.; Xue, Z.; Gevorkian, N.; Pichard, A. D.; Satler, L. F.; Kent, K. M., and Waksman, R. Clopidogrel loading dose (300 versus 600 mg) strategies for patients with stable angina pectoris subjected to percutaneous coronary intervention. Am J Cardiol. 2006 Apr 1; 97(7):984–9.
  230. Wong, P.; Robinson, A.; Shaw, S., and Rodrigues, E. Long term clinical outcome and bleeding complications among hospital survivors with acute coronary syndromes. Postgrad Med J. 2006 Mar; 82(965):224–7.
  231. Wong, S. and Lewis, D. Resistance to antiplatelet therapy: fact or fiction? N Z Med J. 2005 May 20; 118(1215):U1459.
  232. Woodward, M. Lowe GD, Francis LM, Rumley A, Cobbe SM (Institute for International Health, University of Sydney, Sydney, Australia.). A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost. 2(11):1934–40, 2004 Nov. 2004.
  233. Yamamoto, N.; Shiraki, K.; Saitou, Y.; Kawakita, T.; Okano, H.; Sugimoto, K.; Murata, K., and Nakano, T. Ticlopidine induced acute cholestatic hepatitis complicated with pure red cell aplasia. J Clin Gastroenterol. 2004 Jan; 38(1):84.
  234. Yan, B. P.; Clark, D. J., and Ajani, A. E. Oral antiplatelet therapy and percutaneous coronary intervention. Expert Opin Pharmacother. 2005 Jan; 6(1):3–12.
  235. Yang, X.; Alexander, K. P.; Chen, A. Y.; Roe, M. T.; Brindis, R. G.; Rao, S. V.; Gibler, W. B.; Ohman, E. M., and Peterson, E. D. The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol. 2005 Oct 18; 46(8):1490–5.
  236. Yip, H. K.; Wu, C. J.; Hang, C. L.; Chang, H. W.; Hung, W. C.; Yeh, K. H., and Yang, C. H. Serial changes in platelet activation in patients with unstable angina following coronary stenting: evaluation of the effects of clopidogrel loading dose in inhibiting platelet activation. Circ J. 2005 Oct; 69(10):1208–11.
  237. Zhao, L.; Gray, L.; Leonardi-Bee, J.; Weaver, C. S.; Heptinstall, S., and Bath, P. M. Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke. Platelets. 2006 Mar; 17(2):100–4.
  238. Ziegler, S.; Schillinger, M.; Funk, M.; Felber, K.; Exner, M.; Mlekusch, W.; Sabeti, S.; Amighi, J.; Minar, E.; Brunner, M.; Muller, M., and Mannhalter, C. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke. 2005 Jul; 36(7):1394–9.
  239. Zimarino, M.; Renda, G., and De Caterina, R. Optimal duration of antiplatelet therapy in recipients of coronary drug-eluting stents. Drugs. 2005; 65(6):725–32.
Copyright © 2007, Oregon Health & Science University, Portland, Oregon.
Bookshelf ID: NBK10382
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (842K)

Other titles in this collection

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...